Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 89,13 € (+90,82 %). Medianen er 78,43 € (+67,91 %).

Køb	7
Behold	0
Sælg	0

Nyheder Til nyhedsfeedet

MBX Biosciences hits record high at $69.50

MBX Biosciences stock rose to an all‑time high of $69.50 after a one‑year gain of 414% and a 104% increase year‑to‑date. Six analysts recently raised their earnings estimates, while a fair‑value analysis rates the stock as slightly overvalued. Quarterly results are due in two days; the company recently underwent leadership changes with Steve Hoerter as new chairman and CEO and John Smither named permanent CFO. Phase‑2 data for canvuparatid showed a 57% response rate after one year, but the stock initially fell on the news; Stifel raised its price target to $56 and maintained a "Buy" rating after positive MBX‑4291 data. » Mere på de.investing.com
MBX Biosciences reaches new all-time high at $66.66

MBX Biosciences stock rose to a new all-time high of $66.66 and is up 336.31% year-to-date; it currently trades at $65.30, about 1% below the 52-week high. InvestingPro values the stock slightly above its fair value. The company announced leadership changes: Steve Hoerter will be chairman and CEO, John Smither permanent CFO, and co-founder Kent Hawryluk resigned. MBX released Phase 2 data on canvuparatid showing annual response rates of 57%, but the stock later fell; Stifel raised its price target to $56 and maintained a buy rating after positive interim data on MBX-4291. » Mere på de.investing.com
MBX Biosciences: CEO Kent Hawryluk resigns, Steve Hoerter named chairman and CEO

MBX Biosciences shares fell about 8.3% in after-hours trading following the announcement of the leadership change. Steve Hoerter was appointed chairman and chief executive officer effective immediately; Kent Hawryluk resigned as president, CEO and board member. John Smither was promoted from interim to permanent chief financial officer. MBX reaffirmed targets for H2 2026, including a Phase 3 start with Canvuparatid, nomination of a triple GLP-1/GIP/GCGR agonist, and 12-week data for MBX 4291. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde MBX Biosciences en omsætning på 0 € og et nettoresultat på -32,5 mio. €

(EUR)	juni 2026	YoY
Omsætning	0	-
Bruttofortjeneste	0	-
Nettoresultat	-32,5 mio.	97,36 %
EBITDA	-35,79 mio.	118,04 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	2,33 mia. €
Antal aktier	48,16 mio.
Højeste/laveste i 52 uger	64,74 € - 18,01 €
Udbytte	Nej
Beta	0,10
P/E (PE Ratio)	-22,67
PEG (PEG Ratio)	3,89
K/I (PB Ratio)	6,34
P/S (PS Ratio)	0,00

Virksomhedsprofil

MBX Biosciences, Inc., et klinisk biofarmaceutisk selskab, fokuserer på opdagelse og udvikling af præcisionspeptidterapier til behandling af endokrine og metaboliske lidelser. Selskabets førende produktkandidat er MBX 2109, et parathyroideahormon-peptidprodrug, som er i et fase 2-klinisk forsøg designet som en potentiel langtidsvirkende hormonerstatningsbehandling til behandling af kronisk hypoparathyroidisme. Selskabet udvikler desuden MBX 1416, en langtidsvirkende glucagon-like peptide-1 (GLP-1)-receptorantagonist, som er i et fase 1-klinisk forsøg designet som en potentiel behandling af post-bariatrisk hypoglykæmi, en kronisk komplikation efter bariatrisk kirurgi. Derudover udvikler selskabet MBX 4291, en førende produktkandidat inden for fedme, som er i undersøgelser forud for den kliniske udvikling (investigational new drug-enabling studies) designet som et langtidsvirkende og meget potent GLP-1- og glucoseafhængigt insulinotropt polypeptid (GIP)-receptor-co-agonist-prodrug til behandling af fedme og komorbiditeter. Selskabet blev grundlagt i 2018 og har hovedsæde i Carmel, Indiana.